-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J03Y5m4QlYZn715cTW0l4vt4KysvQyyF/b3mqrDb9R4Cns5NsRBbqinfq/3W4csC gjmjTsk5Mox4BFImKkNvLA== 0000950133-03-004202.txt : 20031203 0000950133-03-004202.hdr.sgml : 20031203 20031203111541 ACCESSION NUMBER: 0000950133-03-004202 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20031031 ITEM INFORMATION: Other events FILED AS OF DATE: 20031203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CELSION CORP CENTRAL INDEX KEY: 0000749647 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 521256615 STATE OF INCORPORATION: MD FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14242 FILM NUMBER: 031034324 BUSINESS ADDRESS: STREET 1: 10220-I OLD COLUMBIA PIKE STREET 2: STE I CITY: COLUMBIA STATE: MD ZIP: 21046-1705 BUSINESS PHONE: 4102905390 MAIL ADDRESS: STREET 1: 10220 I OLD COLUMBIA ROAD CITY: COLUMBIA STATE: MD ZIP: 21046 FORMER COMPANY: FORMER CONFORMED NAME: CHEUNG LABORATORIES INC DATE OF NAME CHANGE: 19920703 8-K 1 w92212e8vk.htm CURRENT REPORT e8vk
 
OMB APPROVAL
OMB Number: 3235-0060
Expires: October 31, 2005
Estimated average burden
Hours per response: 15.00

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(D) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):             October 31, 2003                   

Celsion Corporation

(Exact Name of Registrant as Specified in Charter)
         
Delaware
 
000-14242
 
52-1256615
 
 
(State or Other Jurisdiction
 
(Commission
 
(IRS Employer
of Incorporation)
 
File Number)
 
Identification No.)
     
10220-L Old Columbia Road, Columbia, Maryland   21046-1705
 
(Address of principal executive office)   (Zip Code)

Registrant’s telephone number, including area code: (410) 290-5390                   

(Former Name or Former Address, if Changed Since Last Report)

 

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     
    CELSION CORPORATION
     
     
Date: December 3, 2003  By: /s/ Anthony P. Deasey
   
    Executive Vice President—Finance and
    Administration and Chief Financial Officer

 

 

EXHIBIT INDEX

     
Exhibit   Description
 
99.1   Registrant’s Press Release dated December 3, 2003

  EX-99.1 3 w92212exv99w1.htm EXHIBIT 99.1 exv99w1

 

(CELSION LOGO)

For Further Information Contact:

         
Tony Deasey   Steve Chizzik/Ira Weingarten   Richard Cooper/Jennifer Zimmons
Celsion Corporation   Equity Communications   StrategicGrowth International, Inc.
410.290.5390   973.912.0980   212.838.1444
tony@celsion.com   equity@silcom.com   info@sgi-ir.com

CELSION CHANGES FISCAL YEAR END

Columbia, MD –December 03, 2003: CELSION CORPORATION (AMEX: CLN) today announced that, effective December 31, 2003, it is changing its fiscal year end from September 30 to December 31.

Anthony P. Deasey, Celsion’s Chief Financial Officer, commented, “In January of this year, we formed a strategic relationship with Boston Scientific Corporation through which we have agreed to distribute our BPH 800 Microwave Urethroplasty™ product at such time as it is approved by the FDA. This change to a calendar year end will bring our financial year into conformity with that of Boston Scientific Corporation.”

About Celsion: Celsion Corporation, based in Columbia, Maryland, is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused-heat energy delivered by patented microwave technology.

In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX) in which Boston Scientific will initially distribute Celsion’s BPH product worldwide. Boston Scientific currently owns approximately 7% of Celsion’s outstanding stock.

Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.

###

 
 

Celsion Corporation 10220-I Old Columbia Road, Columbia MD 21046-1705 T 410.290-5390 F 410.290.5394

GRAPHIC 4 w92212celsion.gif GRAPHIC begin 644 w92212celsion.gif M1TE&.#EA1P(R`/<``````(````"``("`````@(``@`"`@,#`P,#X2$A(R,C)24E)RWN?GY^_O[_?W M]____P`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````/_[\*"@I("`@/\```#_ M`/__````__\`_P#______R'Y!```````+`````!'`C(`AP```(````"``("` M````@(``@`"`@,#`P,#X2$A(R,C)24E)RWN?GY^_O[_?W]____P`````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````/_[\*"@I("`@/\```#_`/__````__\`_P#______PC^`%,('$BP MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FR MI//JW;OW M@=^_$/X*'DR8L(/#B!,K!D&WL>/'D#N6:`"@LN7+F#-KWLRYLV223#;IY)-0GF0""28T])5%LP')D0=:(F1"""%$ M*>:81QU@00,,+,"``Q>,8!`*'DR`YIH6A%G0"1E@0,*;&CBPP`(-8%"E0"!P M`%I!*(!P000/0$`!!P<:1$$%71K4`:!D9JHI3R98L(!F#&A`T`@1V`B=C1-$ M*M!I'R`Z06;^$0Q*`0`/%!1"!)]BUH`&E5M4G"!@P`@(%`L]8Z$`?I M+C"!!AUP8(&U`$PP*+N580"L0,(2:Y$)&F@@[KL:'$K0`04W[+#"*9BP@<$$ MA5#PP2F`4/"^`IU+P004N(;0!SG:=\"_)W3`(P<&G?NM0AZLS+&M&W3P[T`H M?'#!I!DYYK)(GO+H`!Y7B.<%;)DA+PO;TH+NN4^#TTDN0MTD%#M&>3[(MFEKIT"JP59*RI! M6GH]?+H20"T0!Y\>G\*L-DH?[+`7]5Z9PC4"P#+RRO(%`<2G]2V0!Y9)\.[V MIIE>`084?+K`RP*-P$`$L9%P0*F,%;0!`!H8@0`'.`+4"20"#!@=0FHT`0(. M4($%Z5VI:G>0NV&@!"?X4JF^1[8%>,N!`KR9[5#$.`!(+B$F<``#*'B0`ZRI M2L0CR.H(AQ#E76!8!BS(#1L@JV49;0/^EL*>15Y5&?4]KS(L')ZU7+2@@IB` M,N;[FV4B(!`4L,A%!$%?:]:GKH*@3W@$^0``P#B0^"41(2=HP`-^%T3K,:0$ M]R.7[@Z"`N@4Q(42J%0(`&"!$4+I;0LXHT'>9D2%O*I5,?Q:$4$`+*_5<8P+ MV1L`YCBKIZWN:`5I6T5*6!D&?.MN"_C=`3[5QX64;EGGJURW4CE)_U4&B%6\ M0`:NMKFKI>"+B'J``YQGD%%2@"$WM)-#[O:!$"Q@771$TXM0D`&D%40#K?2C MDWKG@(9`\P$6R*8VMYE-::TKD0,Q6^4DX($7>:U[$'S3J_)6R>&5*G?7$QA% M[`<`7'4Q!=+^REQ!R`7`$JRE4BBPEOJD*(&[51.?M/H=Y1B@)X5(((%.+)4P M.\:`0BY$6&X\"`06P,L6+B"/>S-?!?-%OQH&4II.NIM%$W+#U=0-G`/Y@#WK M*4RO:;$A-Z3B]`#PRZA)BP$*TR1%M-B!4C7@*Y4I)4$JT$GJV))%ZD/?`CZP MN09DK#)S1![UAF6!DHK(`0TH)IB`)JT3"D2,#\#`!3#`5K;VCR`W?"M"YK:` M"ZRUK1B`I4%6%Z;28?$@)[@D!4)PLQ):`*]LY15*9W0WG2[DAA/PP'[TTY\P MP11G()C`IQ@@+J\):P$-V9P^VUD_TXE+J!/9G"?YV8$]1A-G@,O^S`+2R2+" M22L"S,1>J>(&V`P.6FSB#0.!T"SE`Y9;[.*6& MD:<#@4`#&>UQ`7)%R-LE`0.#?$`08(D_N MZ=UH5;E*40Z9#!EP;=]RX-4=M64'&-W^"387.+C&V&\(K'%`Z=L08YKU($P5 MY$'XN=Q/V5);E>H=V@;2.\7U.$@$?:,*]5Q%#-C)R*8)UT[=M3H(G/>SM>-O M3-/5@+O)4R+#/9YTIVB0`]L2(42LG+CX^4J#T%/**3A!$0OR7`7ND<@#L9]( M%T(NO2;D`:%LB`D<1Y^[9;0"LW6B&G^GV1H?6D;"@O)!^K>Y/":$FC"4='23 M/&D=`S`A"FYSE`]R*R-T87<46.61S;O2E07IWX13@L4N,:P![GWTB M%#!5WBBF@+7^GTRI-[%YCI`64:G6V.VTC;A:PQJ=IL=E[G"B@`240L'3%++# MT;%:<3#>S$$+LF7.L?+;!]$>`!SPW$YRS,X&01^L!0)Q$`K0(,`&`0AM!5ZK M=XD$@*K49/)-$+#GKCB)LM;52-`BJX^`C1P'4=$ZB8%B>L!3TQ)NNAP`J55Q M`%]Z/4T&/DQX$-B)8929*K_!`)P@!WAD@UYD3!)I"3(&_/D"!$7#> MV0=LD9:&71D(2G(S4Q=(2\F.\&'!'4'BO(RW]ND]TC5@`0:,=V;T.1#29^8! M7<*\9D1'[]?B3)=0\T"ZAK79BK=^,Z"/>X=0H('EZPIB(XCMGRS^\P"Y*BNX@<\D.,0]"=U`PI0C4?0'P6:H#\, M-SP=H%:#!RP'T`'.8V4&]`&3=1\YEC*3%60'V(`?H"4H!`CT(#WL7'2MR$2(P%@Y0`3P`$OU@%RHB;DP24%40+:51TZ=1<9@#KE-Q`' M4`&_M0`1P(*2@ET)@0(7($_^D@',]'C.5X)..#1>L7$H\!4B-(4+<@)`PA6] M5$QH5`(',`(F4%@F\'HX,V]NXB9A/N(9LF!0DV(9P&(=R.(=T6(=V>(=X MF(=ZN(=-87_Y]X>`&(B".(B$6(B&>(B`B)B(BKB(C-B(COB(D!B)DCB)E%B) MEGB)F)B)4*-[S=&)GOB)H!B*HCB*I%B*IGB*J)B*JKB*K-B*KOB*`'!P%3`> MM%B+MGB+N)B+NKB+O-B+OOB+P!B,PCB,Q%B,QGB,R)B,RKB,S*B+` -----END PRIVACY-ENHANCED MESSAGE-----